An Open-Label Study to Evaluate the Multiple Dose Pharmacokinetics of Canagliflozin (JNJ-28431754) and Metformin Following Once-Daily Administration of 2 Canagliflozin/Metformin XR (150/1,000-mg) Fixed Dose Combination Tablets in Healthy Subjects
Latest Information Update: 30 May 2014
At a glance
- Drugs Canagliflozin/metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Janssen
- 01 Apr 2014 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
- 23 Jan 2014 New trial record